CERTOLIZUMAB PEGOL
Information current as at: 1 September 2025
PBAC meeting date: November 2019
Submission Details
- Brand name:
-
- Cimzia®
- Pharmaceutical company:
- UCB Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Chronic plaque psoriasis (CPP)
- PBAC Submission type:
- Change to recommended listing (Minor)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents - November 2019
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2019 PBAC meeting
-
Opportunity for consumer comment: - Open 28/08/2019 and close 09/10/2019 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2019
-
PBAC outcome published: - Not Recommended (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a065
Page last updated: 30 June 2025